Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial ...

The final, formatted version of the article will be published soon. Objectives This study investigates osimertinib-induced cardiac adverse reactions (CAR) using realworld FDA Adverse Event Reporting ...

Upon approval, the Test will be intended to help identify patients with NSCLC who may respond to treatment with Tagrisso® (Osimertinib), AstraZeneca’s third-generation EGFR-TKI treatment. Roger Moody, ...

The savolitinib and osimertinib combination demonstrates promising efficacy in patients who have progressed on prior EGFR inhibitor therapy. The findings highlight the potential of this novel ...

HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic ...

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression. At a median ...

which will be used in the US to help identify non-small cell lung cancer patients who are likely to respond to AstraZeneca's third-generation EGFR tyrosine kinase inhibitor treatment Tagrisso ...

Macau Institute for Applied Research in Medicine and Health, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau 999078, China Macau ...

This meant I could start targeted therapy—a daily pill that homes in on cancer cells called Osimertinib. Within weeks, the transformation was astounding. After six to eight weeks, scans showed ...